Syneos Health (NASDAQ:SYNH) has been given an average rating of “Buy” by the fourteen analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $50.88.
A number of analysts have weighed in on SYNH shares. KeyCorp reissued a “buy” rating and set a $50.00 target price on shares of Syneos Health in a research report on Thursday, January 4th. ValuEngine cut Syneos Health from a “hold” rating to a “sell” rating in a report on Monday, April 2nd. BidaskClub upgraded Syneos Health from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. SunTrust Banks increased their price target on Syneos Health to $55.00 and gave the stock a “buy” rating in a report on Thursday, March 1st. Finally, Wells Fargo upgraded Syneos Health from a “market perform” rating to an “outperform” rating in a report on Friday, February 23rd.
In other Syneos Health news, CAO Christopher L. Gaenzle sold 1,470 shares of the stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $41.00, for a total transaction of $60,270.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.24% of the stock is currently owned by corporate insiders.
NASDAQ:SYNH traded up $0.50 on Wednesday, reaching $38.25. 107,733 shares of the stock traded hands, compared to its average volume of 1,031,337. The company has a market capitalization of $3,948.05, a PE ratio of 16.85, a P/E/G ratio of 0.95 and a beta of 0.80. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.23 and a current ratio of 1.23. Syneos Health has a 1-year low of $31.10 and a 1-year high of $61.10.
Syneos Health (NASDAQ:SYNH) last released its earnings results on Wednesday, February 28th. The company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.15. The business had revenue of $750.47 million during the quarter, compared to the consensus estimate of $757.94 million. Syneos Health had a negative net margin of 5.18% and a positive return on equity of 10.78%. research analysts predict that Syneos Health will post 2.28 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2018/04/16/syneos-health-synh-receives-50-88-consensus-target-price-from-brokerages.html.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.